代谢综合征对初次全髋关节置换术后再手术与并发症的影响
基于机构全关节登记数据,将1268例按世界卫生组织标准定义的原发性全髋关节置换术代谢综合征患者与无代谢综合征者按年龄、性别和手术年份1:1匹配。代谢综合征患者5年无任何再手术生存率显著更差(93.5% vs 96.1%,HR 1.4,P = .04);按体质指数分层后,体质指数>40 kg/m2者再手术、翻修及假体周围关节感染风险最高。
要点
- 代谢综合征患者初次全髋关节置换术后5年无再手术生存率为93.5%,低于对照组的96.1%(HR 1.4,P = .04)。
- 体质指数>40 kg/m2的代谢综合征患者5年无再手术生存率为85.9%,对照组为96.1%(HR 3.4,P < .001)。
- 体质指数>40 kg/m2的代谢综合征患者5年无翻修生存率为91.7%,对照组为97.3%(HR 2.7,P < .001);无假体周围关节感染再手术生存率为95%,对照组为99%(HR 5.1,P < .001)。
核心结论
- 代谢综合征患者初次全髋关节置换术后再手术风险约为匹配的无代谢综合征对照的1.4倍。
- 体质指数>40 kg/m2的代谢综合征患者再手术风险最高,翻修率和假体周围关节感染率显著更高,提示病态肥胖是代谢综合征之外的关键独立危险因素。
研究设计与样本
- 利用机构全关节登记数据,识别1268例按世界卫生组织定义诊断为代谢综合征并接受初次全髋关节置换术的患者,按年龄、性别和手术年份与无代谢综合征者1:1匹配。
- 代谢综合征患者进一步按世界卫生组织体质指数分类分层;采用Kaplan-Meier分析比较无任何再手术、无翻修和无并发症生存率,临床结局采用Harris髋关节评分评估;术后平均随访5年。
- 证据等级为3级,病例对照研究。
主要发现
- 代谢综合征患者5年无任何再手术生存率显著低于无代谢综合征者(93.5% vs 96.1%,HR 1.4,P = .04)。
- 体质指数>40 kg/m2的代谢综合征患者5年无任何再手术生存率为85.9%,无代谢综合征对照组为96.1%(HR 3.4,P < .001)。
- 体质指数>40 kg/m2的代谢综合征患者5年无翻修生存率为91.7%,对照组为97.3%(HR 2.7,P < .001)。
- 体质指数>40 kg/m2的代谢综合征患者5年无假体周围关节感染再手术生存率为95%,对照组为99%(HR 5.1,P < .001)。
- 两组最终Harris髋关节评分均较术前显著改善且改善程度相似(P < .001)。
关键数值与推荐
- 代谢综合征诊断依据世界卫生组织定义。
- 体质指数分层依据世界卫生组织体质指数分类标准。
- 体质指数>40 kg/m2的代谢综合征患者5年无任何再手术生存率为85.9%,对照组为96.1%(HR 3.4,P < .001)。
- 体质指数>40 kg/m2的代谢综合征患者5年无假体周围关节感染再手术生存率为95%,对照组为99%(HR 5.1,P < .001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metabolic syndrome (MetS) represents a constellation of interrelated conditions including insulin resistance, abdominal obesity, hypertension, and dyslipidemia. The goals of this study are to determine the impact of MetS on implant survivorship, complications, and clinical outcomes after primary total hip arthroplasty (THA). METHODS: Utilizing our institutional total joint registry, 1,268 patients undergoing primary THA were identified with MetS based on the World Health Organization definition and matched 1:1 to those without MetS based on age, gender, and surgical year. MetS patients were further stratified according to the World Health Organization body mass index (BMI) classification to contextualize obesity. Kaplan-Meier analyses were utilized to compare survivorship free of any reoperation, revision, and complications. Clinical outcomes were assessed with Harris hip scores. Mean follow-up after THA was 5 years. RESULTS: MetS patients had significantly worse 5-year survivorship free from any reoperation compared to those without MetS (93.5% vs 96.1%, respectively; hazard ratio [HR] 1.4, P = .04). When stratifying MetS and BMI classification, the BMI >40 kg/m2 had significantly decreased 5-year implant survivorship free from any reoperation (85.9% vs 96.1%, HR 3.4, P < .001), any revision (91.7% vs 97.3%, HR 2.7, P < .001), and reoperation for periprosthetic joint infection (95% vs 99%, HR 5.1, P < .001). Both groups experienced significant and similar improvement in final Harris hip scores (P < .001). CONCLUSION: Patients with MetS had a 1.4-fold increased risk of reoperation after primary THA compared to a matched cohort without the condition. MetS patients with a BMI >40 kg/m2 had the highest risk of reoperation, and had a significantly higher revision and periprosthetic joint infection rates, suggesting that morbid obesity remains a critical, independent risk factor beyond MetS. LEVEL OF EVIDENCE: Level 3, Case-control study.
引用
- Ledford CK, Elstad ZM, Fruth KM, et al. The Impact of Metabolic Syndrome on Reoperations and Complications After Primary Total Hip Arthroplasty. J Arthroplasty. 2022. PMID: 35131392. doi:10.1016/j.arth.2022.01.091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。